Capital World Investors’s Autolus Therapeutics AUTL Stock Holding History
Bought
Maintained
Sold
Other funds holding AUTL
SP
DTC
TAM
AC
NCM
FLSM
OAMG
PL
Capital World Investors's AUTL Position: Q1 2023 in Review
Capital World Investors sold out of Autolus Therapeutics (AUTL) in Q1 2023, closing a stake of 625,000 shares — an estimated $1.19M sold.
Capital World Investors first reported a position in AUTL in Q2 2018 and held it in 19 quarters. The position peaked at $47.4M in Q2 2020. 65 funds tracked by Wall St. Rank hold AUTL as of Q1 2023.
- Capital World Investors reported no remaining Autolus Therapeutics position as of Q1 2023 after selling out during the quarter.
- Capital World Investors sold 625,000 Autolus Therapeutics shares in Q1 2023, an estimated $1.19M.
- Capital World Investors first reported a position in Autolus Therapeutics in Q2 2018 and held it in 19 quarters.
- Capital World Investors's Autolus Therapeutics position peaked at $47.4M in Q2 2020.
- 65 funds tracked by Wall St. Rank held Autolus Therapeutics as of Q1 2023.
Based on Capital World Investors's 13F filing for Q1 2023, filed 15 May 2023.